{"id":675496,"date":"2023-11-06T18:22:02","date_gmt":"2023-11-06T18:22:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=675496"},"modified":"2023-11-06T18:22:02","modified_gmt":"2023-11-06T18:22:02","slug":"behcets-disease-pipeline-clinical-trials-key-companies-abbvie-amgen-nobel-novartis-and-many-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/behcets-disease-pipeline-clinical-trials-key-companies-abbvie-amgen-nobel-novartis-and-many-others_675496.html","title":{"rendered":"Behcet&#8217;s Disease  Pipeline | Clinical Trials, Key Companies &#8211; AbbVie, Amgen, Nobel, Novartis, and many others."},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Behcet&#039;s Disease  Pipeline | Clinical Trials, Key Companies - AbbVie, Amgen, Nobel, Novartis, and many others.\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Behcet&#039;s Disease  Pipeline | Clinical Trials, Key Companies - AbbVie, Amgen, Nobel, Novartis, and many others.\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Behcet&#8217;s Disease Pipeline Insights, 2023&#8243; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Behcet&#8217;s Disease market.<\/div>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/behcets-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Behcet&#8217;s Disease Pipeline Insights, 2023<\/a><\/strong>&#8221; report by DelveInsight outlays comprehensive insights of the present clinical development scenario and growth prospects across the Behcet&#8217;s Disease market. A detailed picture of Behcet&#8217;s Disease pipeline landscape is provided, which includes the disease overview and Behcet&#8217;s Disease treatment guidelines. The assessment part of the report embraces in-depth Behcet&#8217;s Disease commercial assessment and clinical assessment of the Behcet&#8217;s Disease pipeline products from the pre-clinical developmental phase to the marketed phase<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the Key Highlights for Behcet&#8217;s Disease Pipeline&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Key Companies working in Behcet&rsquo;s Disease pipeline include AbbVie, Amgen, Nobel Pharmaceuticals, Novartis Pharmaceuticals, and many others.<\/li>\n<li>The Key Therapies working in Behcet&rsquo;s Disease pipeline includes AIN457, Flucinolone Acetonide, Colchicine, and many others&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Got queries? Click here to know more about the<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/behcets-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\"> Behcet&#8217;s Disease Pipeline landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Behcet&#8217;s Disease&nbsp; Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Behcet&#8217;s disease might be an autoimmune disorder, which means the body&#8217;s immune system mistakenly attacks some of its own healthy cells. It&#8217;s likely that genetic and environmental factors play a role. The signs and symptoms of Behcet&#8217;s disease are considered to be due to inflammation of the blood vessels (vasculitis). The condition can involve arteries and veins of all sizes, damaging them throughout the body. Several genes are associated with the disease. Some researchers believe a virus or bacterium can trigger Behcet&#8217;s disease in people who have certain genes that make them susceptible to Behcet&#8217;s.<\/p>\n<p style=\"text-align: justify;\"><em>&nbsp;<\/em><strong>Learn more by requesting for sample @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/behcets-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Behcet&#8217;s Disease Pipeline&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Behcet&#8217;s Disease Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>AbbVie<\/li>\n<li>Amgen<\/li>\n<li>Nobel Pharmaceuticals<\/li>\n<li>Novartis Pharmaceuticals<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And many others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Behcet&#8217;s Disease Therapies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>AIN457<\/li>\n<li>Flucinolone Acetonide<\/li>\n<li>Colchicine<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>&nbsp;Key Insights&nbsp;<\/li>\n<li>&nbsp;Report Introduction&nbsp;<\/li>\n<li>&nbsp;Executive Summary of Behcet&#8217;s Disease&nbsp;&nbsp;<\/li>\n<li>&nbsp;Disease Background and Overview<\/li>\n<li>&nbsp;Epidemiology and patient population<\/li>\n<li>&nbsp;The United States&nbsp;<\/li>\n<li>&nbsp;EU 5<\/li>\n<li>&nbsp;Behcet&#8217;s Disease&nbsp; &nbsp; Emerging Therapies<\/li>\n<li>Behcet&#8217;s Disease&nbsp; Market Outlook<\/li>\n<li>&nbsp;Market Access and Reimbursement of Therapies<\/li>\n<li>&nbsp;Appendix<\/li>\n<li>&nbsp;Behcet&#8217;s Disease&nbsp; Report Methodology<\/li>\n<li>DelveInsight Capabilities<\/li>\n<li>Disclaimer<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Click here to read more about<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/behcets-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\"> Behcet&#8217;s Disease Pipeline&nbsp;<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=behcets-disease-pipeline-clinical-trials-key-companies-abbvie-amgen-nobel-novartis-and-many-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=behcets-disease-pipeline-clinical-trials-key-companies-abbvie-amgen-nobel-novartis-and-many-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP Behcet&#8217;s Disease Pipeline Insights, 2023&#8243; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Behcet&#8217;s Disease market. Behcet&#8217;s Disease Pipeline Insights, 2023&#8221; report by DelveInsight outlays comprehensive insights of &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/behcets-disease-pipeline-clinical-trials-key-companies-abbvie-amgen-nobel-novartis-and-many-others_675496.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,404],"tags":[],"class_list":["post-675496","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/675496","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=675496"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/675496\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=675496"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=675496"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=675496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}